Challenges for Commercializing Gene Therapies


Gene therapies are poised to enter the US healthcare system within the next 1-2 years as viable treatment options. In response to this burgeoning field, The Institute for Clinical and Economic Review (ICER) convened a Policy Summit in late 2016 to analyze the potential value and challenges of gene therapy treatments.  ICER has released the conclusions from that summit in a white paper, GENE THERAPY: Understanding the Science, Assessing the Evidence, and Paying for Value.  Here’s what we see as the key commercial challenges.